BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 32301013)

  • 1. Current Landscape of Immunotherapy in Genitourinary Malignancies.
    Alhalabi O; Rafei H; Bilen MA; Shah AY
    Adv Exp Med Biol; 2020; 1244():107-147. PubMed ID: 32301013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Landscape of Immunotherapy in Genitourinary Malignancies.
    Ravindranathan D; Alhalabi O; Rafei H; Shah AY; Bilen MA
    Adv Exp Med Biol; 2021; 1342():143-192. PubMed ID: 34972965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunotherapy revolution in genitourinary malignancies.
    U Gandhy S; Madan RA; Aragon-Ching JB
    Immunotherapy; 2020 Aug; 12(11):819-831. PubMed ID: 32594815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
    Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
    Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunotherapy in uropathology].
    Verkarre V; Roussel H; Granier C; Tartour E; Allory Y
    Ann Pathol; 2017 Feb; 37(1):90-100. PubMed ID: 28111042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding and overcoming resistance to immunotherapy in genitourinary cancers.
    Evans ST; Jani Y; Jansen CS; Yildirim A; Kalemoglu E; Bilen MA
    Cancer Biol Ther; 2024 Dec; 25(1):2342599. PubMed ID: 38629578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in genitourinary malignancies.
    Wattenberg MM; Fong L; Madan RA; Gulley JL
    Curr Opin Urol; 2016 Nov; 26(6):501-7. PubMed ID: 27471994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking PD-1/PD-L1 in Genitourinary Malignancies: To Immunity and Beyond.
    Dallos MC; Drake CG
    Cancer J; 2018; 24(1):20-30. PubMed ID: 29360724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for genitourinary tumors.
    Nakayama T; Kitano S
    Int J Urol; 2019 Mar; 26(3):326-333. PubMed ID: 30710374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel immunotherapy combinations for genitourinary cancers.
    Al Harthy M; Redman J; Madan RA
    Expert Opin Biol Ther; 2020 Mar; 20(3):253-262. PubMed ID: 31914333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunotherapy of Renal Cell Carcinoma].
    Poprach A; Lakomý R; Büchler T
    Klin Onkol; 2017; 30(Supplementum3):55-61. PubMed ID: 29239194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging immunotherapy in advanced renal cell carcinoma.
    Mendiratta P; Rini BI; Ornstein MC
    Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials.
    Godwin JL; Zibelman M; Plimack ER; Geynisman DM
    Discov Med; 2014 Dec; 18(101):341-50. PubMed ID: 25549705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel immunotherapies in GU malignancies.
    Drakaki A; McDermott DF
    Curr Oncol Rep; 2013 Jun; 15(3):224-31. PubMed ID: 23519772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel immunotherapy in metastatic renal cell carcinoma.
    Cho YH; Kim MS; Chung HS; Hwang EC
    Investig Clin Urol; 2017 Jul; 58(4):220-227. PubMed ID: 28681030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors.
    Ornstein MC; Calabrese C; Wood LS; Kirchner E; Profusek P; Allman KD; Martin A; Kontzias A; Grivas P; Garcia JA; Calabrese LH; Rini BI
    Clin Genitourin Cancer; 2019 Jun; 17(3):177-182. PubMed ID: 30824360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in genitourinary malignancies.
    Mehta K; Patel K; Parikh RA
    J Hematol Oncol; 2017 Apr; 10(1):95. PubMed ID: 28434403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice.
    Massari F; Nunno VD; Mollica V; Montironi R; Cheng L; Cimadamore A; Blanca A; Lopez-Beltran A
    Immunotherapy; 2019 Dec; 11(17):1507-1521. PubMed ID: 31663411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
    Atkins MB; Clark JI; Quinn DI
    Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The promise of immunotherapy in genitourinary malignancies.
    Zhang T; Armstrong AJ; George DJ; Huang J
    Precis Clin Med; 2018 Dec; 1(3):97-101. PubMed ID: 30687563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.